Why Screening for Type 1 Diabetes Before Symptoms Matter

For decades, type 1 diabetes has been diagnosed the same way: when a person develops symptoms of high blood sugar. By that point, the disease is already advanced and causing problems throughout the body.

What we now understand is that type 1 diabetes doesn't start with symptoms. It begins years earlier as an autoimmune process—the body's immune system attacking the insulin-producing cells in the pancreas. This process happens in silence, with no outward signs that anything is wrong.

Scientists can now identify type 1 diabetes in its earliest stages by screening for islet autoantibodies. These are markers in the blood that show the immune system has begun attacking the pancreas. By testing for these antibodies, doctors can spot the disease long before symptoms appear—even in young children.

This kind of screening represents a shift in how we think about type 1 diabetes: instead of waiting for the disease to announce itself, we can find it early and intervene.

Early detection offers concrete advantages for patients and families. One major benefit is prevention of serious complications. Diabetic ketoacidosis (DKA), a life-threatening emergency that can occur at diagnosis, is less likely to develop when type 1 diabetes is found before symptoms start.

Early detection also opens doors that would otherwise stay closed. People identified with presymptomatic type 1 diabetes can now access approved therapies designed to slow or delay the progression to clinical disease. Additionally, early detection makes it possible to participate in clinical trials testing new treatments currently in development—a crucial step toward finding better options.

Despite these clear benefits, screening for presymptomatic type 1 diabetes is not yet standard practice everywhere. Experts identify several knowledge gaps that need to be addressed before screening can become routine in clinical care.

The field is moving toward making early detection a normal part of how we identify and care for type 1 diabetes. But getting there requires closing these gaps and building systems that can implement screening widely and effectively.

Source: Hormone research in paediatrics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.